Ionis Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Great. Good afternoon, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Ionis here with us today for fireside chat, but we should call it a beachside chat because we are in Miami. Joining us from Ionis is Brett Monia, Chief Executive Officer.
Brett, thank you so much for making the time and joining us today. Before we dive into questions, and I know there's a lot of programs to cover and a very catalyst-rich year for you. Maybe if you could give us an overview of the Ionis platform and portfolio and some of the key catalysts for the company over the next 12 to 18 months.
That sounds great. It's great to be here, Ellie. Thanks. Yeah, let me provide a brief intro on where we are today and where we're headed at Ionis. So -- as I think most people in the audience are aware, we're an RNA -- we're genetic medicines company focused on novel treatments targeting RNA for clinical medicine diseases
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
